Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1

Monoclonal antibodies (mAb) targeting immune checkpoint pathways such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1) may confer durable disease control in several malignancies. In some patients, immune checkpoint mAb cause cutaneous immune-related adverse event...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Immunol Res
Autores principales: Naidoo, Jarushka, Schindler, Katja, Querfeld, Christiane, Busam, Klaus, Cunningham, Jane, Page, David B., Postow, Michael A., Weinstein, Alyona, Lucas, Anna Skripnik, Ciccolini, Kathryn T., Quigley, Elizabeth A., Lesokhin, Alexander M., Paik, Paul K., Chaft, Jamie E., Segal, Neil H., D‘Angelo, Sandra P., Dickson, Mark, Wolchok, Jedd D., Lacouture, Mario E.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5241697/
https://ncbi.nlm.nih.gov/pubmed/26928461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-15-0123
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares